ANALYSIS ON THE CLINICAL DATA OF PULMONARY SPACE-OCCUPYING LESION AND EVALUATION OF THE DIAGNOSTIC EFFICACY OF LUNG CANCER
Download as PDFVolume 4, Issue 1, Pp 35-39, 2021
Author(s)
Wen-qi Li, Min Su*
Affiliation(s)
Department of Oncology, Guangzhou Development District Hospital, Guangzhou, 510730, China
Corresponding Author
Min Su
ABSTRACT
Objective: Based on the pathological result and inspection data of 44 cases of pulmonary space-occupying lesion, this paper discussed the practical value of CT-guided pathological biopsy and three tumor markers being named CEA, NSE and CYFRA21-1 in the detection of lung cancer. Methods: The results of Pathology, immunohistochemistry, CEA, NSE and CYFRA21-1 in 44 cases of confirmed pulmonary space-occupying lesions were collected. This paper calculated the positive rate from unique and united test of the three tumor markers on the lung cancer group and non-malignant group. Chi square test were used to make the comparison between different groups, and then plotting a ROC curve based on the analysis of specificity and sensitivity. Results: The results show 33 cases in lung cancer group, 11 cases in non-malignant group among the 44 pulmonary space-occupying lesion cases. Immunohistochemistry was carried out to check 16 cases. The positive rate of TTF-1and CK7 in adenocarcinoma group was 57.14% while P40 in squamous cell carcinoma was 60%. The positive rate of lung cancer group, including NSE, CYFRA21-1 and the co-detection of three index, were 48.48 %, 78.78% and 81.81%. Respectively, these rate in non-malignant group was 0%, 27.27%, 36.36%. Chi square test showed p<0.05, the differences were statistically significant. The AUC was 0.875 while the sensitivity was 81.8% of tumor markers united test, both higher than the unique test. However, the specificity is 63.3%, lower than the unique test. Besides, the positive rate of CYFRA21-1 among different pathological types of lung cancer showed significantly difference, for the result of chi square test was p < 0.05, which was statistically significant. Conclusion: The study demonstrated that the CT-guided percutaneous lung biopsy was beneficial to detect and later treatment of lung cancer. The results of the tumor marker NSE and CYFRA21-1 unique test are ideal, better than the co-detection of three index. We suggested to give priority to the test of NSE and CYFRA21-1 in the follow-up diagnosis and treatment.
KEYWORDS
Pulmonary space-occupying lesion, CEA, NSE, CYFRA21-1, CT-guided percutaneous lung biopsy
CITE THIS PAPER
Wen-qi Li, Min Su.Analysis on the clinical data of pulmonary space-occupying lesion and evaluation of the diagnostic efficacy of lung cancer. Acta Translational Medicine. 2021, 4(1): 31-35.
REFERENCES
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424.
[2] Nasim F, Sabath BF, Eapen GA. Lung Cancer. Med Clin North Am. 2019;103(3):463-473.
[3] Standard for diagnosis and treatment of primary liver cancer(2019). Electronic Journal of Liver Tumor. 2020;7(01):5-23.
[4] Yang XL, Yu HP, Si TG. Consensus of Chinese experts on percutaneous biopsy of thoracic tumors. Chin J Inter Rad (Electronic Edition). 2021;9(02):117-126.
[5] Deng CJ, Dai FQ, Qian K, et al. Clinical updates of approaches for biopsy of pulmonary lesions based on systematic review. BMC Pulm Med. 2018;18(1):146.
[6] Li W, He XF, Wei YT, Zhang X, Zhang XB, Li J, Li J, Yang J, Xue XD, Xiao YY. Clinical application of CT-guided radiofrequency ablation combined with biopsy synchronously to multiple small nodules of lung metastatic tumors. Natl Med J China. 2018;98(27):2189-2193.
[7] Liu JL, Huang ZB, Zhou J, Li DC. Clinical application and complications of CT-guided percutaneous lung biopsy. Clinical application and complications of Chin J Lng Dis (Electronic Edition). 2019;12(06):767-769.
[8] Hu L, Guo Q, Wen D, Yan J, Du Y. CT-guided percutaneous transthoracic needle biopsy for the diagnosis of non-small cell lung cancer: a retrospective analysis of its diagnostic accuracy. J Intervent Radiol. 2018;27:274-277.
[9] Zhao YD, Zhang N, Yang LJ, Ma HM, Luo LF, Si XH, Wang HW. Application research of CT-guided percutaneous lung biopsy in space-occupying lesions. Int J Respir. 2021;41:367-371.
[10] Griesing S, Kajino T, Tai MC, et al. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells. Cancer Sci. 2017;108(7):1394-1404.
[11] Pelosi G, Scarpa A, Forest F, et al. The impact of immunohistochemistry on the classification of lung tumors. Expert Rev Respir Med. 2016;10(10):1105-1121.
[12] Kriegsmann K, Cremer M, Zgorzelski C, et al. Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer. Pathology. 2019;51(3):240-245.
[13] Jia H, Zhang L, Wang B. The Value of Combination Analysis of Tumor Biomarkers for Early Differentiating Diagnosis of Lung Cancer and Pulmonary Tuberculosis. Ann Clin Lab Sci. 2019;49(5):645-649.
[14] Molina R, Marrades RM, Augé JM, et al. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 2016;193(4):427-437.
[15] Zhang T, Xiang B, Lin Yong P. Predictive value of combined detection tumor markers in the diagnosis of lung cancer. Chin J Prev Med. 2021;55:786-791.